Results 81 to 90 of about 19,374,294 (402)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Around the World in 16 Ways: Searching Internationally for Fall Prevention Strategies

open access: yesPatient Safety, 2020
Pennsylvania fall rates have remained relatively steady over the past six years, ranging from 3.09–3.33 falls per 1,000 patient days. Other studies estimate that hospital falls occur at a rate of 3.56 per 1,000 patient days and 700,000 to 1 million ...
Caitlyn Allen, Susan C. Wallace
doaj   +1 more source

Impact of Language Barriers on Quality of Care and Patient Safety for Official Language Minority Francophones in Canada

open access: yesJournal of Patient Experience, 2018
Introduction: The risks to patient safety and quality of care faced by members of linguistic minority groups have been well-documented. However, little research has focused on the experience of official language minorities in Canada.
Danielle de Moissac, Sarah Bowen
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Patient Safety and Patients' Rights [PDF]

open access: yesAMA Journal of Ethics, 2004
Patient safety can be improved through the implementation of a physician reporting system, in which medical errors can be reported confidentially. Virtual Mentor is a monthly bioethics journal published by the American Medical Association.
openaire   +2 more sources

Patient safety and safety culture in primary health care: a systematic review

open access: yesBMC Family Practice, 2018
BackgroundPatient safety in primary care is an emerging field of research with a growing evidence base in western countries but little has been explored in the Gulf Cooperation Council Countries (GCC) including the Sultanate of Oman.
M. Lawati   +3 more
semanticscholar   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

open access: yesMolecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad   +12 more
wiley   +1 more source

Quality & Safety Update: Resident Teams Recognized, New Fellows Initiate Research [PDF]

open access: yes, 2017
Championing quality and safety is an institutional commitment and a critical part of day-to-day operations in the Department of Surgery. Scott Cowan, MD, FACS, Vice Chair for Quality in the Department, shares an update on current initiatives.

core   +1 more source

The economics of patient safety in primary and ambulatory care

open access: yesOECD Health Working Papers, 2018
Building on published patient safety research literature, this paper aims to broaden the existing knowledge base on safety lapses occurring in primary and ambulatory care settings.
Ane Auraaen, L. Slawomirski, N. Klazinga
semanticscholar   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy